141 related articles for article (PubMed ID: 32216948)
21. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel LRRC4C-ALK fusion in lung adenocarcinoma and outcome of the response to anaplastic lymphoma kinase inhibitors.
Wang H; Li Z; Qi X; Wang W; Lin Y
J Gene Med; 2021 Mar; 23(3):e3316. PubMed ID: 33559138
[No Abstract] [Full Text] [Related]
23. Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.
Ma H; Zhang Q; Duan Q; Zhang Q; Li F
Lung Cancer; 2021 Feb; 152():196-198. PubMed ID: 33386152
[No Abstract] [Full Text] [Related]
24. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.
Shan L; Jiang P; Xu F; Zhang W; Guo L; Wu J; Zeng Y; Jiao Y; Ying J
J Thorac Oncol; 2015 Jun; 10(6):e37-9. PubMed ID: 26001147
[No Abstract] [Full Text] [Related]
25. A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib.
Lin H; Ren G; Liang X
J Thorac Oncol; 2018 Nov; 13(11):e234-e236. PubMed ID: 30368418
[No Abstract] [Full Text] [Related]
26. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
27. A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib.
Zhang J; Zou C; Zhou C; Luo Y; He Q; Sun Y; Zhou J; Ke Z
J Thorac Oncol; 2020 Jun; 15(6):1073-1077. PubMed ID: 32217130
[No Abstract] [Full Text] [Related]
28. Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.
Yang X; Li Y; Duan Q; Zhang Q; He M
J Thorac Oncol; 2021 Mar; 16(3):e17-e19. PubMed ID: 33641723
[No Abstract] [Full Text] [Related]
29. DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.
Zhang J; Huang J; Li Q; Lin H; Luo Z; Chen R
Lung Cancer; 2021 Sep; 159():171-174. PubMed ID: 34266695
[No Abstract] [Full Text] [Related]
30. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
31. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
32. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
33. Ipsilateral breast metastasis from lung adenocarcinoma harboring anaplastic lymphoma kinase or ROS1 rearrangement and significant response after targeted therapy: report of two cases.
Zheng J; Zhou JY; Bao Z; Shen Q; Cao H; Zhou JY
Chin Med J (Engl); 2020 Jul; 133(14):1725-1726. PubMed ID: 32558701
[No Abstract] [Full Text] [Related]
34. Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema.
Van Damme E; Kiselinova M; Van Schoote E
Tumori; 2019 Dec; 105(6):NP35-NP37. PubMed ID: 31023173
[TBL] [Abstract][Full Text] [Related]
35. Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.
Baglivo S; Ricciuti B; Ludovini V; Metro G; Siggillino A; De Giglio A; Chiari R
J Thorac Oncol; 2018 Aug; 13(8):e145-e147. PubMed ID: 30049377
[No Abstract] [Full Text] [Related]
36. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
Zeng L; Xia C; Zhang Y; Yang N
J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
[No Abstract] [Full Text] [Related]
37. Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
Mizugaki H; Hamada A; Shibata T; Hosoda F; Nakamura H; Okuma Y; Shukuya T; Umemura S; Horiike A; Fukui T; Kogure Y; Daga H; Urata Y; Yamada K; Saeki S; Fujisaka Y; Nakamura Y; Sato M; Yoshida T; Hotta T; Oizumi S; Fujiwara Y; Ohe Y; Fujiwara Y
Lung Cancer; 2019 Feb; 128():20-25. PubMed ID: 30642448
[TBL] [Abstract][Full Text] [Related]
38. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
39. A Low Crizotinib Concentration in the Cerebrospinal Fluid Causes Ineffective Treatment of Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer with Carcinomatous Meningitis.
Okimoto T; Tsubata Y; Hotta T; Hamaguchi M; Nakao M; Hamaguchi SI; Hamada A; Isobe T
Intern Med; 2019 Mar; 58(5):703-705. PubMed ID: 30333394
[TBL] [Abstract][Full Text] [Related]
40. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]